WARNING: This product is for research use only, not for human or veterinary use.
Hodoodo CAT#: H326703
CAS#: 154235-83-3
Description: CX-516 ,aslo known as BDP 12 and SPD-420, is an ampakine and nootropic that acts as an AMPA receptor positive allosteric modulator. It was researched as a treatment for Alzheimer's disease under the brand name Ampalex, and was also being examined as a treatment for ADHD. CX-516 showed good in vitro activity and positive results in animal tests, the human trials proved disappointing due mainly to low potency and short half-life. However, CX-516 is still widely used in animal research into the ampakine drugs and is the standard reference compound that newer, more potent drugs of this class such as farampator and CX-717 are compared to.
Hodoodo Cat#: H326703
Name: CX-516
CAS#: 154235-83-3
Chemical Formula: C14H15N3O
Exact Mass: 241.12
Molecular Weight: 241.294
Elemental Analysis: C, 69.69; H, 6.27; N, 17.41; O, 6.63
Synonym: CX-516; CX 516; CX516; BDP 12; BDP-12; BDP12; SPD-420; SPD420; brand name: Ampalex.
IUPAC/Chemical Name: 1-(quinoxalin-6-ylcarbonyl)piperidine
InChi Key: ANDGGVOPIJEHOF-UHFFFAOYSA-N
InChi Code: InChI=1S/C14H15N3O/c18-14(17-8-2-1-3-9-17)11-4-5-12-13(10-11)16-7-6-15-12/h4-7,10H,1-3,8-9H2
SMILES Code: O=C(N1CCCCC1)C2=CC=C3N=CC=NC3=C2
Appearance: Solid powder
Purity: >98% (or refer to the Certificate of Analysis)
Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility: Soluble in DMSO, not in water
Shelf Life: >2 years if stored properly
Drug Formulation: This drug may be formulated in DMSO
Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code: 2934.99.9001
More Info:
| Biological target: | |
| In vitro activity: | |
| In vivo activity: |
The following data is based on the product molecular weight 241.29 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass | 1 mg | 5 mg | 10 mg |
|---|---|---|---|
| 1 mM | 1.15 mL | 5.76 mL | 11.51 mL |
| 5 mM | 0.23 mL | 1.15 mL | 2.3 mL |
| 10 mM | 0.12 mL | 0.58 mL | 1.15 mL |
| 50 mM | 0.02 mL | 0.12 mL | 0.23 mL |
| Formulation protocol: | |
| In vitro protocol: | |
| In vivo protocol: |
1: Gibert-Rahola J, Villena-Rodriguez A. Glutamatergic drugs for schizophrenia treatment. Actas Esp Psiquiatr. 2014 Sep;42(5):234-41. Epub 2014 Sep 1. PubMed PMID: 25179095.
2: O'Neill MJ, Witkin JM. AMPA receptor potentiators: application for depression and Parkinson's disease. Curr Drug Targets. 2007 May;8(5):603-20. Review. PubMed PMID: 17504104.
3: Olsen CK, Kreilgaard M, Didriksen M. Positive modulation of glutamatergic receptors potentiates the suppressive effects of antipsychotics on conditioned avoidance responding in rats. Pharmacol Biochem Behav. 2006 Jun;84(2):259-65. Epub 2006 Jun 19. PubMed PMID: 16782180.
4: Visser PJ, Scheltens P, Verhey FR. Do MCI criteria in drug trials accurately identify subjects with predementia Alzheimer's disease? J Neurol Neurosurg Psychiatry. 2005 Oct;76(10):1348-54. PubMed PMID: 16170074; PubMed Central PMCID: PMC1739362.
5: Danysz W. CX-516 (Cortex Pharmaceuticals Inc). IDrugs. 1999 Aug;2(8):814-22. PubMed PMID: 16127658.
6: O'Neill MJ, Bleakman D, Zimmerman DM, Nisenbaum ES. AMPA receptor potentiators for the treatment of CNS disorders. Curr Drug Targets CNS Neurol Disord. 2004 Jun;3(3):181-94. Review. PubMed PMID: 15180479.
7: Danysz W. CX-516 Cortex pharmaceuticals. Curr Opin Investig Drugs. 2002 Jul;3(7):1081-8. Review. PubMed PMID: 12186271.
8: Danysz W. Positive modulators of AMPA receptors as a potential treatment for schizophrenia. Curr Opin Investig Drugs. 2002 Jul;3(7):1062-6. Review. PubMed PMID: 12186268.
9: Lindén AM, Yu H, Zarrinmayeh H, Wheeler WJ, Skolnick P. Binding of an AMPA receptor potentiator ([3H]LY395153) to native and recombinant AMPA receptors. Neuropharmacology. 2001 Jun;40(8):1010-8. PubMed PMID: 11406192.
